HIGHLIGHTS
- who: Max Topp from the Affimed GmbH, Heidelberg, Germany have published the article: Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies, in the Journal: (JOURNAL)
- what: The aim of the study was to determine the safety and tolerability of AFM11 administered intravenously at weekly intervals over a period of 4 weeks (1 cycle) in patients with NHL, investigating escalating doses and different infusion durations. There was no formal statistical analysis in this study; results are presented using descriptive statistics for continuous variables that include the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.